Literature DB >> 33115729

Intravenous Albumin for Mitigating Hypotension and Augmenting Ultrafiltration during Kidney Replacement Therapy.

Nicole Hryciw1, Michael Joannidis2, Swapnil Hiremath3, Jeannie Callum4,5, Edward G Clark6.   

Abstract

Among its many functions, owing to its oversized effect on colloid oncotic pressure, intravascular albumin helps preserve the effective circulatory volume. Hypoalbuminemia is common in hospitalized patients and is found especially frequently in patients who require KRT either for AKI or as maintenance hemodialysis. In such patients, hypoalbuminemia is strongly associated with morbidity, intradialytic hypotension, and mortality. Intravenous albumin may be administered in an effort to prevent or treat hypotension or to augment fluid removal, but this practice is controversial. Theoretically, intravenous albumin administration might prevent or treat hypotension by promoting plasma refilling in response to ultrafiltration. However, clinical trials have demonstrated that albumin administration is not nearly as effective a volume expander as might be assumed according to its oncotic properties. Although intravenous albumin is generally considered to be safe, it is also very expensive. In addition, there are potential risks to using it to prevent or treat intradialytic hypotension. Some recent studies have suggested that hyperoncotic albumin solutions may precipitate or worsen AKI in patients with sepsis or shock; however, the overall evidence supporting this effect is weak. In this review, we explore the theoretical benefits and risks of using intravenous albumin to mitigate intradialytic hypotension and/or enhance ultrafiltration and summarize the current evidence relating to this practice. This includes studies relevant to its use in patients on maintenance hemodialysis and critically ill patients with AKI who require KRT in the intensive care unit. Despite evidence of its frequent use and high costs, at present, there are minimal data that support the routine use of intravenous albumin during KRT. As such, adequately powered trials to evaluate the efficacy of intravenous albumin in this setting are clearly needed.
Copyright © 2021 by the American Society of Nephrology.

Entities:  

Keywords:  acute kidney injury; albumin; chronic hemodialysis; dialysis; hemodialysis; hypotension; intradialytic hypotension; intravenous albumin; kidney replacement therapy; ultrafiltration

Mesh:

Substances:

Year:  2020        PMID: 33115729      PMCID: PMC8259476          DOI: 10.2215/CJN.09670620

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  54 in total

1.  Albumin-mediated regulation of cellular glutathione and nuclear factor kappa B activation.

Authors:  A M Cantin; B Paquette; M Richter; P Larivée
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

2.  Albumin controversy continues. Meta-analysis has affected use of albumin.

Authors:  R Patey; G Wilson; T Hulse
Journal:  BMJ       Date:  1999-02-13

3.  A protocol-based treatment for intradialytic hypotension in hospitalized hemodialysis patients.

Authors:  S Emili; N A Black; R V Paul; C J Rexing; M E Ullian
Journal:  Am J Kidney Dis       Date:  1999-06       Impact factor: 8.860

Review 4.  Structure of serum albumin.

Authors:  D C Carter; J X Ho
Journal:  Adv Protein Chem       Date:  1994

Review 5.  Vascular oxidant stress and inflammation in hyperhomocysteinemia.

Authors:  Louisa Papatheodorou; Norbert Weiss
Journal:  Antioxid Redox Signal       Date:  2007-11       Impact factor: 8.401

Review 6.  How can we prevent intradialytic hypotension?

Authors:  Rajiv Agarwal
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-11       Impact factor: 2.894

7.  Hypoalbuminemia seems to be associated with a higher rate of hospitalization in hemodialysis patients.

Authors:  Sandra Azevedo Antunes; Maria Eugenia F Canziani; Arnon Farias Campos; Rosana Quintela Brandão Vilela
Journal:  J Bras Nefrol       Date:  2016-03

Review 8.  Intradialytic Blood Pressure Abnormalities: The Highs, The Lows and All That Lies Between.

Authors:  Magdalene M Assimon; Jennifer E Flythe
Journal:  Am J Nephrol       Date:  2015-11-20       Impact factor: 3.754

9.  The higher mortality associated with low serum albumin is dependent on systemic inflammation in end-stage kidney disease.

Authors:  Filipa Caeiro Alves; Jia Sun; Abdul Rashid Qureshi; Lu Dai; Sunna Snaedal; Peter Bárány; Olof Heimbürger; Bengt Lindholm; Peter Stenvinkel
Journal:  PLoS One       Date:  2018-01-03       Impact factor: 3.240

10.  Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study.

Authors:  Suvi T Vaara; Anna-Maija Korhonen; Kirsi-Maija Kaukonen; Sara Nisula; Outi Inkinen; Sanna Hoppu; Jouko J Laurila; Leena Mildh; Matti Reinikainen; Vesa Lund; Ilkka Parviainen; Ville Pettilä
Journal:  Crit Care       Date:  2012-10-17       Impact factor: 9.097

View more
  7 in total

1.  A randomized trial of albumin infusion to prevent intradialytic hypotension in hospitalized hypoalbuminemic patients.

Authors:  Etienne Macedo; Bethany Karl; Euyhyun Lee; Ravindra L Mehta
Journal:  Crit Care       Date:  2021-01-06       Impact factor: 9.097

2.  Intravenous albumin for the prevention of hemodynamic instability during sustained low-efficiency dialysis: a randomized controlled feasibility trial (The SAFER-SLED Study).

Authors:  Edward G Clark; Lauralyn McIntyre; Irene Watpool; Jennifer W Y Kong; Tim Ramsay; Elham Sabri; Mark Canney; Gregory L Hundemer; Pierre-Antoine Brown; Manish M Sood; Swapnil Hiremath
Journal:  Ann Intensive Care       Date:  2021-12-13       Impact factor: 6.925

3.  The Use of I.V. Albumin During Kidney Replacement Therapy: A Survey of Nephrologists and Intensivists.

Authors:  Ryan J Chan; William Beaubien-Souligny; Samuel A Silver; Sean M Bagshaw; Ron Wald; Pierre-Antoine Brown; Swapnil Hiremath; Jennifer W Y Kong; Edward G Clark
Journal:  Kidney Int Rep       Date:  2021-12-08

4.  Albumin is an interface between blood plasma and cell membrane, and not just a sponge.

Authors:  Jens van de Wouw; Jaap A Joles
Journal:  Clin Kidney J       Date:  2021-10-05

5.  Albumin infusion in hospitalized patients with acute heart failure: a retrospective cohort study.

Authors:  Lei Wang; Yun-Tao Zhao
Journal:  BMC Cardiovasc Disord       Date:  2022-08-06       Impact factor: 2.174

6.  Hyperoncotic Albumin Solution in Continuous Renal Replacement Therapy Patients.

Authors:  Zachary O'Brien; Mark Finnis; Martin Gallagher; Rinaldo Bellomo
Journal:  Blood Purif       Date:  2021-08-12       Impact factor: 3.348

Review 7.  New Trends in the Utilization of Intravenous Fluids.

Authors:  Mohammad Tinawi
Journal:  Cureus       Date:  2021-04-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.